Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Haematological cancer

Determinants of response and resistance to T cell-engaging therapies in multiple myeloma

Nature Reviews Clinical Oncology volume 20, pages 505–506 (2023)Cite this article

Subjects

Bispecific T cell engagers offer a novel treatment approach for patients with multiple myeloma, although mechanisms of resistance are largely unknown. Here, we discuss the implications of a recent report from Friedrich et al. that highlights the importance of pre-treatment T cell characteristics for a response to the T cell engager elranatamab and how these data might be used to inform future study and trial design.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Immune cell subsets at baseline and in response to BCMA-targeted bispecific T cell-engaging therapies.

References

  1. Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell, https://doi.org/10.1016/j.ccell.2023.02.008 (2023).

    Article  PubMed  Google Scholar 

  2. Dhodapkar, K. M. et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 3, 490–501 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Samur, M. K. et al. Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors. Blood 140 (Supplement 1), 2106–2107 (2022).

    Article  Google Scholar 

  4. Lancman, G. et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2, 423–433 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021).

    Article  CAS  PubMed  Google Scholar 

  7. Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022).

    Article  CAS  PubMed  Google Scholar 

  8. Verkleij, C. P. M. et al. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget 11, 4076–4081 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cortes-Selva, D. et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1. Blood 140 (Supplement 1), 241–243 (2022).

    Article  Google Scholar 

  10. Haber, L. et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci. Rep. 11, 14397 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA

    Shonali Midha & Kenneth C. Anderson

  2. Division of Hematology, Brigham and Women’s Hospital, Boston, MA, USA

    Shonali Midha & Kenneth C. Anderson

Authors
  1. Shonali Midha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth C. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth C. Anderson.

Ethics declarations

Competing interests

K.C.A. has acted as a consultant of AstraZeneca, Bristol Myers Squibb and Janssen. S.M. declares no competing interests

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Midha, S., Anderson, K.C. Determinants of response and resistance to T cell-engaging therapies in multiple myeloma. Nat Rev Clin Oncol 20, 505–506 (2023). https://doi.org/10.1038/s41571-023-00775-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00775-w

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer